Spire by St Brides

Destiny Pharma #DEST – Developing Novel Medicines that Prevent Serious Infections. Alan Green talks to CEO Neil Clark

  • Two exciting late stage clinical assets – XF-73 and NTCD-M3
  • China Medical Systems – new XF-73 programme in China
  • NTCD-M3 Phase 3 studies
  • Spore COV – JV progress and Innovate funding
  • Cash runway and upcoming value inflection points

Our Clients

Blencowe Resources
Item 2
Item 2
Item 2
Item 2
Item 2
Item 2
Item 2
Item 2
Item 2
Item 2